TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02031055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 with a light tracer dose of [14C]FTD
Description: A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 with a light tracer dose of [14C] TPI
Description: A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
Study: NCT01000155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Study: NCT00007631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin 0.1% cream or placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo for same amount of time
Study: NCT02303457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 Laser surgery
Description: Patients were randomly assigned to CO2 laser surgery group and open Surgery group.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Surgery
Description: Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
Study: NCT04015271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation + Repetitive Task Practice
Description: Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Video + Repetitive Task Practice
Description: Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
Study: NCT05164692

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax
Description: In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT03530683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
Study: NCT02031055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
Study: NCT03121261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study: NCT00488540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Suppository
Study: NCT03121261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study: NCT02794428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Description: Eflornithine\*, 2 tablets, Oral, Daily for 18 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eflornithine placebo
Description: Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
Study: NCT01190488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End-of-Life / Advanced Care Decision Aid
Description: Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: TAU
Study: NCT00513123

Intervention type: PROCEDURE
Intervention: Colposcopy
Description: As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
Study: NCT03504527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: double combinations
Description: inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Study: NCT02796365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
Study: NCT03155269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Beverage Powder
Description: The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Non fortified beverage Powder
Description: The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
Study: NCT02139969

Intervention type: DEVICE
Intervention: GreenLight XPS Laser System
Study: NCT00466440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
Study: NCT04443426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral 3-hydroxybutyrate salts
Description: Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Placebo
Description: Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester
Description: Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
Study: NCT02162381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a single dose of methylphenidate 10 mg to be taken orally in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guidance
Description: subjects will be given an explanation and advice about how to perform well in visual field testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guidance
Description: subjects will be given an explanation and advice about how to perform well in visual field testing
Study: NCT03952377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX600
Description: Transforaminal Epidural Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX600
Description: Transforaminal Epidural Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transforaminal Epidural Injection
Study: NCT01224769

Intervention type: DRUG
Intervention: bendamustine +/- rituximab
Study: NCT03699956

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RRx-001 + eLOOP Device
Description: RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/carboplatin plus etoposide
Description: Standard of care platinum doublet chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/carboplatin plus etoposide
Description: Standard of care platinum doublet chemotherapy
Study: NCT01856296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT01001286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questscope Non-Formal Education
Description: Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questscope Non-Formal Education
Description: Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators).
Study: NCT01188759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks.
Study: NCT02619565

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples at Day 0 and also if there is an evolution of the disease
Study: NCT00466440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose, then po QD until unblinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
Study: NCT05246631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Group A consisted of patients given 5 mg intravenous dexamethasone after induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol Injection
Description: Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
Study: NCT03207607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control snack
Description: Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin snack
Description: Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein snack
Description: Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat snack
Description: Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil snack
Description: Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack skipping
Description: no snack
Study: NCT03291249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Anti CD3 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Anti CD3 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Anti CD3 mAb

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH
Study: NCT02608827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resperate®-InterCure Ltda
Description: The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music group (GC)
Description: The patients in this arm will hear slow music - Music group (GC).
Study: NCT04897724

Intervention type: OTHER
Group type: OTHER
Intervention: dental composite
Description: clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
Study: NCT03487146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoperfusion(HP)
Description: These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
Study: NCT02317796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
Study: NCT03718221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care FIT Screening Strategy
Description: Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeoMail FIT Screening Strategy
Description: Patients in treated neighborhoods will receive kits at the same time.
Study: NCT02611076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking for Good Intervention in Spanish (SS-SP)
Description: Assessments will occur at six-month intervals, through 24 months.
Study: NCT00466440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
Study: NCT02611076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: Assessments will occur at six-month intervals, through 24 months.
Study: NCT02006810

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Induction of endothelial function variations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of endothelial function variations
Study: NCT00714025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10mg, daily, PO
Study: NCT01370291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active Risperidone and active rTMS
Description: active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and sham Risperidone
Description: active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS and active Risperidone
Description: active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
Study: NCT00466440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg po BID, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg po BID, six 21-day cycles
Study: NCT03463291

Intervention type: DEVICE
Intervention: MRI
Description: * T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values.
Study: NCT03627572

Intervention type: OTHER
Intervention: No intervention
Description: Not applicable (no intervention)

Intervention type: OTHER
Intervention: No intervention
Description: Not applicable (no intervention)
Study: NCT04843956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided biopsy
Description: Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)
Study: NCT00360035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Description: 60 mg q2wks
Study: NCT02121808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)